Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab with or without chemotherapy followed by T-DM1 in HER2-positive metastatic breast cancer
NL-OMON44863Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab, trastuzumab, trastuzumab emtansine, paclitaxel and vinorelbine in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Overall survival at 24 months. Started Jan 2015; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON44863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44863.